Hopp til hovedinnhold

MOG-antistoff sykdom (MOGAD)

Sist oppdatert: Sist revidert:
Sist revidert av:
  1. Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S, Sugimoto K, Oji S, Uzawa A, Asseyer S, Cooper G, Jarius S, Bellmann-Strobl J, Ruprecht K, Siebert N, Masuda H, Uchida T, Ohtani R, Nomura K, Meinl E, Kuempfel T, Paul F, Kuwabara S. Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. J Neurol Neurosurg Psychiatry. 2020 Nov 20:jnnp-2020-324422. PMID: 33219036. PubMed  
  2. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 3;15(1):134. PMID: 29724224  PubMed  
  3. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019 May;266(5):1280-1286. PMID: 30569382  PubMed  
  4. Wang M, Zeng P, Du C, Xue H, Cui Z, Zhang H, Jia D, Zhang C. Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders. Mult Scler Relat Disord. 2021 Aug;53:103035. PMID: 34077831. PubMed  
  5. Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021 Sep;20(9):762-772. Erratum in: Lancet Neurol. 2021 Oct;20(10):e6. PMID: 34418402. PubMed  
  6. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert MW, Ringelstein M, Rommer PS, Ayzenberg I, Ruprecht K, Klotz L, Asgari N, Zrzavy T, Höftberger R, Tobia R, Buttmann M, Fechner K, Schanda K, Weber M, Asseyer S, Haas J, Lechner C, Kleiter I, Aktas O, Trebst C, Rostasy K, Reindl M, Kümpfel T, Paul F, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020 Sep 3;17(1):261. PMID: 32883348 PubMed  
  7. Pace S, Orrell M, Woodhall M, Palace J, Leite MI, Irani SR, Waters P, Handel AE. Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):334-335. PMID: 34261747 PubMed  
  8. Dale RC, Ramanathan S. Clinical decision making in MOG antibody-associated disease. Lancet Neurol. 2021 Sep;20(9):695-697. PMID: 34418387.
  9. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018 Oct;25:66-72. PMID: 30048919.  PubMed  
  10. Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, Mariotto S, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2022 May 1;79(5):518-525. PMID: 35377395 PubMed  
  11. Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017 Sep;23(10):1377-1384. PMID: 27885065.  PubMed  
  12. Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S, Sugimoto K, Oji S, Uzawa A, Asseyer S, Cooper G, Jarius S, Bellmann-Strobl J, Ruprecht K, Siebert N, Masuda H, Uchida T, Ohtani R, Nomura K, Meinl E, Kuempfel T, Paul F, Kuwabara S. Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. J Neurol Neurosurg Psychiatry. 2020 Nov 20:jnnp-2020-324422. PMID: 33219036. PubMed  
  13. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020. pmid:32554760  PubMed  
  14. Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E; NOMADMUS study group. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol. 2021 May;28(5):1659-1664. PMID: 33528851. PubMed  
  15. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017 Dec 1;140(12):3128-3138. doi: 10.1093/brain/awx276. Erratum in: Brain. 2018 Apr 1;141(4):e31. PMID: 29136091  PubMed  
  16. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert MW, Ringelstein M, Rommer PS, Ayzenberg I, Ruprecht K, Klotz L, Asgari N, Zrzavy T, Höftberger R, Tobia R, Buttmann M, Fechner K, Schanda K, Weber M, Asseyer S, Haas J, Lechner C, Kleiter I, Aktas O, Trebst C, Rostasy K, Reindl M, Kümpfel T, Paul F, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020 Sep 3;17(1):261. PMID: 32883348 PubMed  
  17. Buciuc M, Sechi E, Flanagan EP, Lopez-Chiriboga AS. Unfavorable outcome in highly relapsing MOGAD encephalitis. J Neurol Sci 2020. pmid:32911390  PubMed  
  18. Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E; NOMADMUS study group. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol. 2021 May;28(5):1659-1664. PMID: 33528851. PubMed  
  19. Jain K, Cherian A, K P D, P R, Thomas B, J N. "FLAMES: A novel burning entity in MOG IgG associated disease". Mult Scler Relat Disord. 2021 Apr;49:102759. PMID: 33508569. PubMed  
  20. Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, Oommen AT, Reshma SS, Kamble N, Thomas PT, Maya B, Pal PK, Mahadevan A. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. J Neurol. 2021 Apr;268(4):1419-1433. PMID: 33188477. PubMed  
  21. Dale RC, Ramanathan S. Clinical decision making in MOG antibody-associated disease. Lancet Neurol. 2021 Sep;20(9):695-697. PMID: 34418387.
  22. Wang M, Zeng P, Du C, Xue H, Cui Z, Zhang H, Jia D, Zhang C. Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders. Mult Scler Relat Disord. 2021 Aug;53:103035. PMID: 34077831. PubMed  
  23. Jain K, Cherian A, K P D, P R, Thomas B, J N. "FLAMES: A novel burning entity in MOG IgG associated disease". Mult Scler Relat Disord. 2021 Apr;49:102759. PMID: 33508569. PubMed  
  24. Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, Oommen AT, Reshma SS, Kamble N, Thomas PT, Maya B, Pal PK, Mahadevan A. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. J Neurol. 2021 Apr;268(4):1419-1433. PMID: 33188477. PubMed  
  • Hanne Marie Bøe Lunde, spesialist i nevrologi PhD
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med
  • Øivind Fredvik Torkildsen, spesialist i nevrologi, professor PhD
  • Christian Vedeler, spesialist i nevrologi, professor dr med